
Chinese General Practice ›› 2026, Vol. 29 ›› Issue (35): 5249-5258.DOI: 10.12114/j.issn.1007-9572.2025.0342
• Article • Previous Articles Next Articles
Received:2025-07-13
Revised:2025-12-02
Published:2026-12-15
Online:2026-10-26
Contact:
XU Xiaodan
通讯作者:
徐晓丹
作者简介:作者贡献:
陈健、徐晓丹进行文章的构思与设计;诸梦琳、夏开建、刘骁、王甘红进行数据收集及数据整理,并进行统计学处理与代码报错解决;陈健撰写论文并进行论文的修订;徐晓丹对文章整体负责,监督管理。
基金资助:CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2025.0342
| 组别 | 例数 | 性别[例(%)] | 年龄[M(P25,P75),岁] | BMI[M(P25,P75),kg/m2] | 空腹血糖[例(%)] | 胰腺炎病因[例(%)] | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 男 | 女 | 正常 | 升高 | 胆源性 | 高脂血症性 | 酒精性 | 其他 | ||||
| 训练队列 | 353 | 192(54.4) | 161(45.6) | 50.0(36.0,65.0) | 22.8(20.3,25.1) | 290(82.2) | 63(17.8) | 168(47.6) | 75(21.2) | 30(8.5) | 80(22.7) |
| 验证队列 | 89 | 41(46.1) | 48(53.9) | 45.0(35.0,60.0) | 22.8(20.8,25.4) | 76(85.4) | 13(14.6) | 48(53.9) | 16(18.0) | 10(11.2) | 15(16.9) |
| 检验统计量值 | 1.66a | 1.52 | -0.64 | 0.32a | 2.66a | ||||||
| P值 | 0.198 | 0.248 | 0.575 | 0.571 | 0.447 | ||||||
| 组别 | 静息收缩压[M(P25,P75),mmHg] | 吸烟史[例(%)] | PTA[M(P25,P75),%] | 白蛋白[M(P25,P75),g/L] | 直接胆红素[M(P25,P75),μmol/L] | 总胆红素[M(P25,P75),μmol/L] | 总胆固醇[M(P25,P75),mmol/L] | 甘油三酯[M(P25,P75),mmol/L] | |||
| 无 | 有 | ||||||||||
| 训练队列 | 130(120,140) | 266(75.4) | 87(24.6) | 44.22 (33.55,55.77) | 41.20 (36.30,43.70) | 6.00 (3.50,12.30) | 22.23 (13.68,58.14) | 7.81 (6.46,10.09) | 1.22 (0.95,1.64) | ||
| 验证队列 | 128(120,138) | 73(82.0) | 16(18.0) | 39.95 (28.79,51.58) | 41.10 (35.00,43.40) | 5.40 (3.40,14.20) | 30.78 (11.97,66.69) | 7.84 (6.62,9.67) | 1.22 (0.95,1.72) | ||
| 检验统计量值 | 1.88 | 1.42a | 2.21 | 0.75 | 0.28 | -0.08 | -0.07 | -0.55 | |||
| P值 | 0.238 | 0.234 | 0.070 | 0.608 | 0.829 | 0.459 | 0.783 | 0.652 | |||
| 组别 | 血红蛋白( | 血小板计数( | 丙氨酸氨基转移酶[M(P25,P75),U/L] | 天冬氨酸氨基转移酶[M(P25,P75),U/L] | 碱性磷酸酶[M(P25,P75),U/L] | 尿素氮[M(P25,P75),mg/dL] | 血钙( | 血钾[M(P25,P75),U/L] | 血钠( | ||
| 训练队列 | 136.98±23.95 | 252.79±96.73 | 30.20 (15.40,81.40) | 105.78 (75.95,141.05) | 108.30 (79.70,155.20) | 6.51(4.74,9.23) | 2.25±0.19 | 3.81(3.56,4.08) | 138.98±3.42 | ||
| 验证队列 | 138.59±22.86 | 234.20±93.07 | 36.20 (20.10,62.90) | 98.40 (74.00,136.00) | 112.00 (77.20,159.20) | 6.23(4.53,7.51) | 2.19±0.18 | 3.95(3.64,4.19) | 138.75±3.50 | ||
| 检验统计量值 | -0.59b | 1.67b | 0.31 | 0.07 | 0.89 | 1.68 | 3.09b | -1.53 | 0.56b | ||
| P值 | 0.568 | 0.103 | 0.542 | 0.369 | 0.809 | 0.227 | 0.074 | 0.096 | 0.57 | ||
| 组别 | 尿酸[M(P25,P75),μmol/L] | 血肌酐[M(P25,P75),μmol/L] | 降钙素原[M(P25,P75),ng/mL] | 白细胞计数[M(P25,P75),×109/L] | 中性粒细胞计数[M(P25,P75),×109/L] | 淀粉酶[M(P25,P75),U/L] | C反应蛋白[M(P25,P75),mg/L] | TyG[M(P25,P75)] | NLR[M(P25,P75)] | ||
| 训练队列 | 356.20 (298.80,430.60) | 63.92 (53.74,75.13) | 0.89 (0.38,2.16) | 11.17 (8.74,13.97) | 9.25 (6.63,12.42) | 303.04 (131.28,586.36) | 12.90 (4.97,31.81) | 10.50 (9.29,11.49) | 6.76 (5.79,7.79) | ||
| 验证队列 | 362.20 (290.00,453.00) | 65.95 (55.69,77.26) | 0.95 (0.52,1.90) | 11.66 (8.84,14.39) | 9.84 (6.59,13.01) | 385.33 (161.58,697.09) | 16.50 (4.88,34.98) | 10.43 (9.34,11.28) | 7.03 (5.95,7.84) | ||
| 检验统计量值 | -0.97 | -0.65 | 0.11 | -0.26 | -0.31 | -1.58 | -0.47 | 1.06 | -0.25 | ||
| P值 | 0.402 | 0.482 | 0.416 | 0.729 | 0.718 | 0.135 | 0.646 | 0.428 | 0.609 | ||
Table 1 Comparison of baseline characteristics between training and validation cohorts
| 组别 | 例数 | 性别[例(%)] | 年龄[M(P25,P75),岁] | BMI[M(P25,P75),kg/m2] | 空腹血糖[例(%)] | 胰腺炎病因[例(%)] | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 男 | 女 | 正常 | 升高 | 胆源性 | 高脂血症性 | 酒精性 | 其他 | ||||
| 训练队列 | 353 | 192(54.4) | 161(45.6) | 50.0(36.0,65.0) | 22.8(20.3,25.1) | 290(82.2) | 63(17.8) | 168(47.6) | 75(21.2) | 30(8.5) | 80(22.7) |
| 验证队列 | 89 | 41(46.1) | 48(53.9) | 45.0(35.0,60.0) | 22.8(20.8,25.4) | 76(85.4) | 13(14.6) | 48(53.9) | 16(18.0) | 10(11.2) | 15(16.9) |
| 检验统计量值 | 1.66a | 1.52 | -0.64 | 0.32a | 2.66a | ||||||
| P值 | 0.198 | 0.248 | 0.575 | 0.571 | 0.447 | ||||||
| 组别 | 静息收缩压[M(P25,P75),mmHg] | 吸烟史[例(%)] | PTA[M(P25,P75),%] | 白蛋白[M(P25,P75),g/L] | 直接胆红素[M(P25,P75),μmol/L] | 总胆红素[M(P25,P75),μmol/L] | 总胆固醇[M(P25,P75),mmol/L] | 甘油三酯[M(P25,P75),mmol/L] | |||
| 无 | 有 | ||||||||||
| 训练队列 | 130(120,140) | 266(75.4) | 87(24.6) | 44.22 (33.55,55.77) | 41.20 (36.30,43.70) | 6.00 (3.50,12.30) | 22.23 (13.68,58.14) | 7.81 (6.46,10.09) | 1.22 (0.95,1.64) | ||
| 验证队列 | 128(120,138) | 73(82.0) | 16(18.0) | 39.95 (28.79,51.58) | 41.10 (35.00,43.40) | 5.40 (3.40,14.20) | 30.78 (11.97,66.69) | 7.84 (6.62,9.67) | 1.22 (0.95,1.72) | ||
| 检验统计量值 | 1.88 | 1.42a | 2.21 | 0.75 | 0.28 | -0.08 | -0.07 | -0.55 | |||
| P值 | 0.238 | 0.234 | 0.070 | 0.608 | 0.829 | 0.459 | 0.783 | 0.652 | |||
| 组别 | 血红蛋白( | 血小板计数( | 丙氨酸氨基转移酶[M(P25,P75),U/L] | 天冬氨酸氨基转移酶[M(P25,P75),U/L] | 碱性磷酸酶[M(P25,P75),U/L] | 尿素氮[M(P25,P75),mg/dL] | 血钙( | 血钾[M(P25,P75),U/L] | 血钠( | ||
| 训练队列 | 136.98±23.95 | 252.79±96.73 | 30.20 (15.40,81.40) | 105.78 (75.95,141.05) | 108.30 (79.70,155.20) | 6.51(4.74,9.23) | 2.25±0.19 | 3.81(3.56,4.08) | 138.98±3.42 | ||
| 验证队列 | 138.59±22.86 | 234.20±93.07 | 36.20 (20.10,62.90) | 98.40 (74.00,136.00) | 112.00 (77.20,159.20) | 6.23(4.53,7.51) | 2.19±0.18 | 3.95(3.64,4.19) | 138.75±3.50 | ||
| 检验统计量值 | -0.59b | 1.67b | 0.31 | 0.07 | 0.89 | 1.68 | 3.09b | -1.53 | 0.56b | ||
| P值 | 0.568 | 0.103 | 0.542 | 0.369 | 0.809 | 0.227 | 0.074 | 0.096 | 0.57 | ||
| 组别 | 尿酸[M(P25,P75),μmol/L] | 血肌酐[M(P25,P75),μmol/L] | 降钙素原[M(P25,P75),ng/mL] | 白细胞计数[M(P25,P75),×109/L] | 中性粒细胞计数[M(P25,P75),×109/L] | 淀粉酶[M(P25,P75),U/L] | C反应蛋白[M(P25,P75),mg/L] | TyG[M(P25,P75)] | NLR[M(P25,P75)] | ||
| 训练队列 | 356.20 (298.80,430.60) | 63.92 (53.74,75.13) | 0.89 (0.38,2.16) | 11.17 (8.74,13.97) | 9.25 (6.63,12.42) | 303.04 (131.28,586.36) | 12.90 (4.97,31.81) | 10.50 (9.29,11.49) | 6.76 (5.79,7.79) | ||
| 验证队列 | 362.20 (290.00,453.00) | 65.95 (55.69,77.26) | 0.95 (0.52,1.90) | 11.66 (8.84,14.39) | 9.84 (6.59,13.01) | 385.33 (161.58,697.09) | 16.50 (4.88,34.98) | 10.43 (9.34,11.28) | 7.03 (5.95,7.84) | ||
| 检验统计量值 | -0.97 | -0.65 | 0.11 | -0.26 | -0.31 | -1.58 | -0.47 | 1.06 | -0.25 | ||
| P值 | 0.402 | 0.482 | 0.416 | 0.729 | 0.718 | 0.135 | 0.646 | 0.428 | 0.609 | ||
| 模型 | 准确度(%) | 灵敏度(%) | 特异度(%) | PPV(%) | NPV(%) | F1分数(%) | AUC |
|---|---|---|---|---|---|---|---|
| LR | 80.37 | 77.06 | 83.64 | 82.35 | 78.63 | 79.62 | 0.89(0.84~0.93) |
| DCT | 82.65 | 86.24 | 79.09 | 80.34 | 85.29 | 83.19 | 0.86(0.80~0.91) |
| RF | 77.63 | 75.23 | 80.00 | 78.85 | 76.52 | 77.00 | 0.89(0.85~0.93) |
| XGBoost | 75.34 | 72.48 | 78.18 | 76.70 | 74.14 | 74.53 | 0.87(0.82~0.92) |
| LNN | 84.47 | 77.06 | 91.82 | 90.32 | 80.16 | 83.17 | 0.91(0.86~0.95) |
Table 2 Summary of overall performance metrics for the five models
| 模型 | 准确度(%) | 灵敏度(%) | 特异度(%) | PPV(%) | NPV(%) | F1分数(%) | AUC |
|---|---|---|---|---|---|---|---|
| LR | 80.37 | 77.06 | 83.64 | 82.35 | 78.63 | 79.62 | 0.89(0.84~0.93) |
| DCT | 82.65 | 86.24 | 79.09 | 80.34 | 85.29 | 83.19 | 0.86(0.80~0.91) |
| RF | 77.63 | 75.23 | 80.00 | 78.85 | 76.52 | 77.00 | 0.89(0.85~0.93) |
| XGBoost | 75.34 | 72.48 | 78.18 | 76.70 | 74.14 | 74.53 | 0.87(0.82~0.92) |
| LNN | 84.47 | 77.06 | 91.82 | 90.32 | 80.16 | 83.17 | 0.91(0.86~0.95) |
| [1] |
|
| [2] |
中华医学会外科学分会胰腺外科学组. 中国急性胰腺炎诊治指南(2021)[J]. 浙江实用医学, 2021, 26(6): 511-519, 535. DOI: 10.16794/j.cnki.cn33-1207/r.2021.06.003.
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
李海山,季流,毛庆,等. 血清KIM-1、UMOD、miR-29a水平对急性胰腺炎并发急性肾损伤的预测价值[J]. 现代消化及介入诊疗, 2024, 29(7): 865-868.
|
| [13] |
何勇,王宇,张艳君. RRI、CAR及SII与重症急性胰腺炎并发急性肾损伤的相关性分析[J]. 中国急救复苏与灾害医学杂志, 2024, 19(9): 1202-1205.
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
孙颖,王雨婷. 个体化预测重症急性胰腺炎患者并发急性肾损伤风险列线图模型的建立及验证[J]. 肝胆外科杂志, 2024, 32(3): 201-205.
|
| [29] |
朱尚,陈瑶,孙文斌,等. 急性胰腺炎合并急性肾损伤的风险列线图预测模型的建立及临床意义[J]. 肝胆胰外科杂志, 2023, 35(10): 590-594.
|
| [1] | XIA Ying, YU Jiayang, GUO Shenao, HONG Xin. Construction of a Carotid Plaque Risk Prediction Model among High-risk Cardiovascular Populations [J]. Chinese General Practice, 2026, 29(33): 4861-4867. |
| [2] | HU Jian, LIU Min, JIAO Zengtao, JING Wenzhan, LIANG Wannian. Research on the Risk Level Assessment of Respiratory Infectious Disease Transmission: a Case Study of COVID-19-infected Public Places [J]. Chinese General Practice, 2026, 29(32): 4738-4744. |
| [3] | LIN Zehua, ZHANG Lan, DAI Shanshan, WEI Yuanyuan, LI Xingli, MA Yingchun. Evaluation and Comparison of Multidimensional Functional Disability in Geriatric Comorbidities and Comorbid Acute Kidney Injury [J]. Chinese General Practice, 2026, 29(32): 4777-4782. |
| [4] | LIU Yang, FENG Xiaojie, CHEN Jieyu, LUO Ren, ZHAO Xiaoshan, BI Jianlu. Revealing the Relationship between Lifestyle and Sub-health Based on Machine Learning: a Cross-sectional Study in Guangdong Province [J]. Chinese General Practice, 2026, 29(26): 3829-3837. |
| [5] | CAO Yixin, LI Yongzhi, WEI Lingxi, ZHOU Yan, GAO Fei, YU Qi. Application Status of Traditional Computational Methods and Machine Learning in Cancer Drug Repositioning [J]. Chinese General Practice, 2026, 29(22): 3226-3232. |
| [6] | FENG Yuxi, WANG Jinjin, CAI Yi, ZHU Runzhi, ZHU Qin. Research Progress on Protein Lactylation in Kidney Diseases [J]. Chinese General Practice, 2026, 29(21): 3056-3063. |
| [7] | CHEN Annan, YAN Zhixin, ZHANG Jian, SHEN Bo, DING Xiaoqiang, SONG Nana. Acidic Preconditioning Activates the Sodium-hydrogen Exchanger 1 to Regulate Intracellular pH Homeostasis and Reduce Renal Ischemia-reperfusion Injury [J]. Chinese General Practice, 2026, 29(12): 1607-1617. |
| [8] | WANG Tingting, LIN Zehua, MA Yingchun, Committee of Kidney Disease Rehabilitation, Chinese Association of Rehabilitation Medicine. Specification of Rehabilitation Service for Elderly Patients with Comorbidity Complicated with Acute Kidney Injury [J]. Chinese General Practice, 2026, 29(11): 1361-1366. |
| [9] | MIN Yeping, XUE Yao, FENG Tongbao, ZHANG He, LIU Fujing. Effect of Blood Pressure Response Index on Acute Kidney Injury in Elderly Patients with Severe Pneumonia Shock [J]. Chinese General Practice, 2026, 29(02): 207-212. |
| [10] | GUO Shengteng, ZHANG Fenfen, WAN Di, YU Dongmei, WANG Qinghua. Risk Factors for Severe Acute Pancreatitis Complicated with Acute Lung Injury: a Meta-analysis [J]. Chinese General Practice, 2025, 28(20): 2546-2554. |
| [11] | XIONG Xin, LI Yang, SHI Feng, YANG Lian, DUAN Wei, CHEN Bei, LI Yong, ZHAO Linwei, FU Quanshui, FAN Xiaoping, YANG Guoqing. Research on the Measurement System and Calibration of Thoracolumbar Vertebral Density Based on Artificial Intelligence [J]. Chinese General Practice, 2025, 28(19): 2398-2406. |
| [12] | WANG Xiaoyu, FENG Zhenzhen, WANG Jun, GUO Xiaochuan, LI Jiansheng. Risk Factors for Acute Kidney Injury in Acute Respiratory Distress Syndrome: a Systematic Review [J]. Chinese General Practice, 2025, 28(12): 1527-1537. |
| [13] | ZHANG Pei, YANG Meng, GAO Chunlin, XIA Zhengkun. Study on the Intervention and Prognosis of Modified Lifting Powder on Acute Kidney Injury and Acute Kidney Disease in Children [J]. Chinese General Practice, 2025, 28(11): 1376-1382. |
| [14] | DU Huijie, LIU Xingyu, XU Minghuan, YANG Xuezhi, ZHANG Huiqin, MO Jiali, LU Yi, KUANG Jie. Advances in the Prognostic Prediction of Acute Ischemic Stroke: Using Machine Learning Predictive Models as an Example [J]. Chinese General Practice, 2025, 28(05): 554-560. |
| [15] | YUE Haitao, HE Chanchan, CHENG Yuyou, ZHANG Sencheng, WU You, MA Jing. Coronary Heart Disease Risk Prediction Model Based on Machine Learning [J]. Chinese General Practice, 2025, 28(04): 499-509. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||